22157.jpg
Outlook on the AI-based Drug Discovery Global Market to 2035 - Industry Trends and Forecasts
May 12, 2022 06:03 ET | Research and Markets
Dublin, May 12, 2022 (GLOBE NEWSWIRE) -- The "AI-based Drug Discovery Market: Distribution by Drug Discovery Steps, Therapeutic Area and Key Geographies: Industry Trends and Global Forecasts,...
22157.jpg
Global Pharmaceuticals Outlook 2022: Digitalization of the Pharmaceuticals Value Chain is Opening up New Growth Opportunities for Stakeholders
May 04, 2022 07:08 ET | Research and Markets
Dublin, May 04, 2022 (GLOBE NEWSWIRE) -- The "Global Pharmaceuticals Outlook, 2022" report has been added to ResearchAndMarkets.com's offering. The report offers an outlook for the global...
New Logo.png
Provectus Biopharmaceuticals Announces Acceptance of PV-10® Immunotherapy Abstract for Metastatic Uveal Melanoma at American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
April 27, 2022 10:00 ET | Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, April 27, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of investigational cancer immunotherapy PV-10, a formulation of...
22157.jpg
Outlook on the KRAS Inhibitors Global Market to 2028 - Key Drivers and Challenges
April 27, 2022 05:28 ET | Research and Markets
Dublin, April 27, 2022 (GLOBE NEWSWIRE) -- The "Global KRAS Inhibitors Market & Clinical Trials Forecast 2028" report has been added to ResearchAndMarkets.com's offering. The advancement in...
New Logo.png
Provectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent Application for Use of PV-10® Immunotherapy in Hematology
April 26, 2022 07:30 ET | Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, April 26, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the United States Patent and Trademark Office (USPTO) has allowed US patent application 16/688,319,...
New Logo.png
Provectus Biopharmaceuticals Seeks Stockholder Approval at 2022 Annual Meeting for Authority to Undertake Reverse Split of Outstanding Equities and Reduce Number of Authorized Equities by Same Ratio
April 19, 2022 16:00 ET | Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, April 19, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that, in conjunction with the filing of the Company’s preliminary 2022 proxy statement (Pre-14A), Provectus’...
New Logo.png
Provectus Biopharmaceuticals Names Aru Narendran, MD, PhD to Scientific Advisory Board
April 14, 2022 07:30 ET | Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, April 14, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced the addition of Aru Narendran, MD, PhD to the Company’s Scientific Advisory Board. Dr. Narendran is a...
New Logo.png
Provectus Biopharmaceuticals Announces Presentation of Multiple Protein Kinase Signaling Targets, including WNK1, for PV-10® Immunotherapy at American Association for Cancer Research (AACR) 2022 Annual Meeting
April 11, 2022 07:30 ET | Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, April 11, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that preclinical research on systemic administration of investigational cancer immunotherapy PV-10 (rose...
Global Pharmaceutical Contract Development And Manufacturing Organization (CMO) Markets, Analysis & Forecasts 2016-2021, 2021-2026F, 2031F
April 11, 2022 04:53 ET | Research and Markets
Dublin, April 11, 2022 (GLOBE NEWSWIRE) -- The "Pharmaceutical Contract Development And Manufacturing Organization (CMO) Global Market Report 2022: By Type, By Research, By End-User" report has been...
New Logo.png
Provectus Biopharmaceuticals Announces Synthesis of New Halogenated Xanthene Small Molecule
March 24, 2022 07:00 ET | Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, March 24, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company has successfully developed and manufactured a second halogenated xanthene (HX), adding to...